GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial
Authors:
- 1 September 2025
- journal article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (9) , 885
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Current Understanding of the Pathophysiology of Idiopathic Intracranial HypertensionCurrent Neurology and Neuroscience Reports, 2025
- Efficacy of Tirzepatide Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched StudyEndocrinology, Diabetes & Metabolism, 2025
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Facilitators and Barriers to Weight Loss Among Patients With Idiopathic Intracranial HypertensionJournal of Neuro-Ophthalmology, 2024
- Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial HypertensionEye, 2024
- Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial HypertensionCephalalgia, 2023
- The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trialBrain, 2023
- The expanding spectrum of idiopathic intracranial hypertensionEye, 2022
- Nearest-Neighbors Matching for Case–Control Study Analyses: Better Risk Factor Identification From a Study of Sporadic Campylobacteriosis in the United StatesEpidemiology, 2022
- Idiopathic intracranial hypertension: consensus guidelines on managementJournal of Neurology, Neurosurgery & Psychiatry, 2018